Medios AG announced the closure of its Aschaffenburg facility, operated by its wholly owned subsidiary Medios Solutions Aschaffenburg GmbH, as part of an optimization of its Germany-wide manufacturing network. Production has already been relocated to other sites, and the company assures uninterrupted supply to pharmacies and hospitals. The Aschaffenburg site accounted for approximately 10% of the production volume of Medios Group’s German manufacturing facilities. The measure affects 32 employees, for whom Medios is seeking fair compensation.
The decision comes amid sustained margin pressure in patient-specific formulations, particularly due to price regulatory adjustments. Medios is countering this with efficiency measures under its Operational Excellence Program. In Germany, Medios operates a network of six GMP (Good Manufacturing Practice) manufacturing facilities for patient-specific therapies. The Aschaffenburg site had been operating at below-average profitability with declining capacity utilization, making continued economic operation unfeasible. Structural renovation work required at the site accelerated the implementation of the closure.
Thomas Meier, CEO of Medios AG, stated: “With a view to ensuring a reliable supply for our customers and maintaining capacity utilization at all sites, we are now optimizing our successful regional presence strategy and consistently developing it further. With Mannheim and Stuttgart, we have two high-performing Medios sites in southern Germany, ensuring that a reliable supply is maintained.”
The company highlighted key events for the 2026 financial year, including the Half-Year Financial Report on August 12, participation in the Berenberg and Goldman Sachs 15th German Corporate Conference in Munich from September 21 to 23, the Medios Capital Markets Day in Breda on September 28/29, and the Quarterly Statement as of September 30 on November 10.
Medios AG is a leading provider of Specialty Pharma in Europe, with locations in Germany, the Netherlands, Belgium, and Spain. The company supports key partners in the supply chain with innovative solutions and intelligent services, focusing on pioneering individualized medicine to make innovative therapies available together with pharmacies, specialist practices, and pharmaceutical companies. Medios AG is Germany's first listed specialty pharmaceutical company, with shares listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) and included in the SDAX selection index.
For more information, visit Medios Group or view the original release on New Media Wire.
